ClinicalTrials.gg
CompletedNCT00820755NEXTUpdated May 5, 2014Results posted

Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of Cetuximab plus Platinum-based Doublet Chemotherapy and Cetuximab 500 mg/m^2 in Non-Small Cell Lung Cancer (NSCLC), sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-05.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
583
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 2 under way, none of them phase 3. Cetuximab · Carcinoma, Non-Small-Cell Lung.

Enrollment
4th of 51
583 · median 63
Started
2009
with 3 others
Phase 3
5 of 52
none open now
Registered
36th of 52
by date
Lead sponsor
3 of 52
Merck KGaA, Darmstadt, Germany

Among the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2009, is one of 5 in phase 3, and was the 36th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This open-label, randomized, multinational, non-comparative, phase IIIb trial with 2 parallel groups will screen about 1400 subjects with stage IIIB non-small cell lung cancer (NSCLC) with pleural effusion or stage IV NSCLC. It is expected that of approximately 1200 (85 percent) subjects who will be included, about 1000 will be Caucasian; about 120 Asian, and the remainder (about 80) will be of other ethnic origin (that is neither Caucasian nor Asian). Approximately 480 (40 percent) subjects are expected to be free of progression at the end of combination treatment with cetuximab and platinum-based chemotherapy. These subjects will be eligible for randomization to intravenous cetuximab maintenance therapy with either 500 milligram per square meter (mg/m\^2) every 2 weeks or 250 mg/m\^2 weekly (q1w); about 240 subjects are expected per group.

The trial will be performed in a community practice setting, with approximately 230 centers participating in the trial worldwide (planned countries are Argentina, Australia, Austria, Belgium, Brazil, Chile, China, Colombia, Czech Republic, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Mexico, Netherlands, Poland, Portugal, Russia, Singapore, Slovakia, South Africa, South Korea, Spain, Switzerland, Taiwan, Turkey, United Kingdom and Venezuela). With noncompetitive enrollment, approximately 4 to 8 subjects are expected to be enrolled at each center. Enrollment in the individual centers is generally limited to a maximum of 8 subjects. If any of these subjects does not receive trial treatment for any reason or discontinue all trial treatment at the first visit, additional subjects may be enrolled until 8 subjects were treated. The primary endpoint of the trial will be overall survival time from inclusion into the trial to death. Additional secondary efficacy endpoints will be time to treatment failure, tumor response, and disease control rate. Other endpoints will include safety and toxicity, compliance with maintenance therapy, subject satisfaction and translational research (TR) (for subjects with tumor samples available).

03

Conditions studied

  • Non-Small Cell Lung Cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has given written before any trial-related activities are carried out
  • Male or female, greater than or equal to (>=)18 years of age at the time of informed consent, inpatient or outpatient
  • Diagnosis of or cytologically confirmed NSCLC, stage IIIB NSCLC with pleural effusion or stage IV
  • Presence of at least 1 uni-dimensionally measurable index lesion, whereby index lesions must not lie in a previously irradiated area
  • (ECOG) performance status (PS) of 0 or 1 at inclusion in the trial
  • White blood count>= 3 * 10\^9 per liter (/L) with neutrophils >= 1.5 * 10\^9 /L , count >=100 * 10\^9 /L , and >= 5.6 millimole per liter (mmol/L) (9 gram per deciliter [g/dL])
  • Total less than or equal to (=\<)1.5 * (ULN) range
  • (ASAT) and alanine aminotransferase (ALAT) =\< 5 * ULN
  • (GFR) >=60 milliliter per minute (mL/min). The (CrCl) estimated based on the Cockroft-Gault formula is used as a surrogate for the GFR
  • Effective that is, barrier method (condoms, diaphragm), oral, injectable or implant birth control, for both male and female subjects during the whole trial period and for at least 6 months after the end of trial treatment, if the risk of conception exists
  • Recovered from relevant toxicities prior to inclusion in the trial

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to Epidermal Growth Factor Receptor (EGFR)-targeting therapy
  • Previous chemotherapy for NSCLC; or adjuvant (radio-)chemotherapy is allowed if it was finished 6 months prior to start of trial treatment
  • Major surgery within 30 days prior to inclusion in the trial
  • Prior chest irradiation within 90 days prior to inclusion in the trial (palliative radiation of bone lesions is allowed)
  • Participation in another clinical trial or treatment with any agent(s) within 30 days prior to inclusion in the trial
  • Concurrent chronic systemic immune therapy, chemotherapy for disease other than cancer, or hormone therapy for the treatment of cancer not indicated in the trial protocol
  • Documented or symptomatic
  • Pre-existing ascites Grade >= 2 and/or pericardial effusion Grade >= 2
  • Superior vena cava syndrome contra-indicating hydration
  • Previous in the last 5 years except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix
  • Active infection (infection requiring intravenous antibiotics), including active tuberculosis, known and declared (HIV)
  • Myocardial infarction within 6 months prior to inclusion into the trial, uncontrolled congestive heart failure; or any current Grade 3 or 4 cardio-vascular disorder despite treatment
  • Known reaction to any of the components of trial treatments
  • Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria (NCI-CTC) Grade >= 2 and/or ototoxicity Grade >= 2, except if due to trauma or mechanical impairment due to tumor mass
  • History of significant neurologic or psychiatric disorders including dementia, seizures, bipolar disorder
  • Medical or psychological condition that would not permit the subject to complete the trial or sign
  • Legal incapacity or limited legal capacity
  • Known drug abuse
  • Pregnancy (absence to be confirmed by serum beta-human chorionic gonadotropin [beta-HCG test]) or lactation period
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
583 participants (actual)

Study arms

  • Active comparator
    Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy

    Drug: Cetuximab plus Platinum-based Doublet Chemotherapy

  • Active comparator
    Cetuximab 500 mg/m^2 every 2 weeks

    Drug: Cetuximab 500 mg/m^2

  • Active comparator
    Cetuximab 250 mg/m^2 weekly

    Drug: Cetuximab 250 mg/m^2

Interventions

  • DrugCetuximab plus Platinum-based Doublet Chemotherapy

    Single first dose of cetuximab 400 mg/m\^2 infusion will be administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m\^2 intravenous infusion over 60 min q1w with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy will be administered as intravenous infusion as per study center included: vinorelbine 25 mg/m\^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m\^2 on D1; or gemcitabine 1250 mg/m\^2 on D1 and D8+cisplatin 75 mg/m\^2 on D1; or gemcitabine 1000 mg/m\^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 milligram\*hour/milliliter (mg\*hr/mL) on D1; or Docetaxel 75 mg/m\^2 on D1+cisplatin 75 mg/m\^2 on D1; or paclitaxel 175 mg/m\^2 on D1+cisplatin 80 mg/m\^2 on D1; or paclitaxel 200 mg/m\^2 on D1+carboplatin at dose to reach AUC6 mg\*hr/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.

  • DrugCetuximab 500 mg/m^2

    Drug page: Cetuximab

    Subjects who will be free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 500 mg/m\^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.

    Also known as: Erbitux

  • DrugCetuximab 250 mg/m^2

    Drug page: Cetuximab

    Subjects who will free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 250 mg/m\^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.

    Also known as: Erbitux

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) Time

    The OS time is defined as the time from trial inclusion to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier.

    Time frame: Time from trial inclusion to death or last day known to be alive, reported between day of first participant included, that is, Jan 2009 until cut-off date (17 Dec 2011)

  2. Percentage of Participants With 1-year Overall Survival

    The OS time is defined as the time from trial inclusion to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier. Percentage of participants who were still alive until one year after the last participant was included (March 2010).

    Time frame: Time from trial inclusion to death or last day known to be alive, reported between day of first participant included, that is, Jan 2009 until one year after the last participant was included (March 2010)

Secondary outcomes

  1. Overall Survival (OS) Time (From Randomization to Cetuximab Maintenance Regimen Until Death)

    The OS time is defined as the time from randomization in cetuximab maintenance regimen to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier.

    Time frame: Time from randomization in cetuximab maintenance regimen to death or last day known to be alive, reported between day of first participant randomized, that is, May 2009 until cut-off date (17 Dec 2011)

  2. Time to Treatment Failure

    Time to treatment failure is defined as the time from trial inclusion to date of either first occurrence of progression, discontinuation of treatment due to progression or adverse event, withdrawal of consent or lost to follow up, start of further anticancer therapy, or death, whichever is earlier. Participants without events are censored either at the time of their last drug intake, or on the day of inclusion (Day 1) if they received no study drug.

    Time frame: Time from trial inclusion to treatment failure or last drug intake, reported between day of first participant included, that is, Jan 2009 until cut-off date (17 Dec 2011)

  3. Time to Treatment Failure (From Randomization to Cetuximab Maintenance Regimen Until Death)

    Time from randomization in cetuximab maintenance regimen to date of either first occurrence of progression, discontinuation of treatment due to progression or adverse event, withdrawal of consent or lost to follow up, start of further anticancer therapy, or death, whichever is earlier. Participants without events are censored either at the time of their last drug intake, or on the day of randomization (Day 1 of maintenance therapy) if they received no study drug.

    Time frame: Time from randomization in cetuximab maintenance regimen to treatment failure or last drug intake, reported between day of first participant randomized, that is, May 2009 until cut-off date (17 Dec 2011)

  4. Percentage of Participants With Best Unconfirmed Tumor Response in the Combination Therapy Phase

    The response rate is defined as the percentage of participants having achieved complete response (CR) or partial response (PR) as the unconfirmed best overall response (BOR) according to centrally reviewed investigator assessments based on an independent review charter (IRC). As per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: CR = Disappearance of all target lesions; PR = at least 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

    Time frame: Evaluations were performed every 2 cycles during combination therapy period until progression and at the end of combination therapy period, reported between day of first participant included, that is, Jan 2009, until cut-off date, (17 Dec 2011)

  5. Percentage of Participant With Best Unconfirmed Tumor Response for the Whole Study Period

    The response rate is defined as the percentage of participants having achieved CR and PR as the BOR according to IRC assessment in combination therapy phase and radiological assessments (based on response evaluation criteria in solid tumors \[RECIST\] Version 1.0) in the maintenance therapy phase. As per RECIST v1.0 for target lesions and assessed by MRI: CR = Disappearance of all target lesions; PR = at least 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

    Time frame: Evaluations were performed every 2 cycles during combination therapy and 6-weekly during maintenance therapy period until progression and at end of both periods, reported between day of first participant included, Jan 2009 until cut-off date (17 Dec 2011)

  6. Percentage of Participants With Disease Control in the Combination Therapy Phase

    The disease control rate is defined as the percentage of participants having achieved complete response or partial response or stable disease as the unconfirmed BOR according to IRC assessment.

    Time frame: Evaluations were performed every 2 cycles during combination therapy period until progression and at the end of combination therapy period, reported between day of first participant included, that is, Jan 2009, until cut-off date, (17 Dec 2011)

  7. Percentage of Participants With Disease Control for the Whole Study Period

    The disease control rate is defined as the percentage of participants having achieved complete response or partial response or stable disease as the unconfirmed best overall response according to IRC assessment in combination therapy phase and radiological assessments (based on RECIST Version 1.0 criteria) in the maintenance therapy phase.

    Time frame: Evaluations were performed every 2 cycles during combination therapy and 6-weekly during maintenance therapy period until progression and at end of both periods, reported between day of first participant included, Jan 2009 until cut-off date (17 Dec 2011)

07

Results

Posted May 5, 2014
Limitations and caveats
Enrollment was stopped prematurely when cetuximab did not gain regulatory approval in this indication.

Participant flow

First/last participants (informed consent): January 2009/17 March 2010. Clinical data cut-off: 17 December 2011

Period 1: Combination Therapy Phase
Participant flow — Period 1: Combination Therapy Phase
MilestoneCetuximab 250 mg/m^2 q1w + Platinum-based Doublet ChemotherapyCetuximab 500 mg/m^2 Every 2 WeeksCetuximab 250 mg/m^2 Weekly
Started58300
Completed31300
Not completed27000
Withdrew: Adverse event7700
Withdrew: Death2800
Withdrew: Protocol violation400
Withdrew: Lost to follow-up100
Withdrew: Withdrawal by subject2100
Withdrew: Progressive disease11400
Withdrew: Sympt. deterioration w/o pd by imaging1400
Withdrew: Other1100
Period 2: Maintenance Therapy Phase
Participant flow — Period 2: Maintenance Therapy Phase
MilestoneCetuximab 250 mg/m^2 q1w + Platinum-based Doublet ChemotherapyCetuximab 500 mg/m^2 Every 2 WeeksCetuximab 250 mg/m^2 Weekly
Started0157154
Completed0112109
Not completed04545
Withdrew: Investigational study phase ongoing04545

Outcome measures

PrimaryOverall Survival (OS) Time

The OS time is defined as the time from trial inclusion to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier.

Time frame:
Time from trial inclusion to death or last day known to be alive, reported between day of first participant included, that is, Jan 2009 until cut-off date (17 Dec 2011)
Reported as:
Median · months
Overall Survival (OS) Time
monthsCetuximab 500 mg/m^2 Every 2 WeeksCetuximab 250 mg/m^2 Weekly
Overall Survival (OS) Time16.1 (13.6 to 18.2)15.5 (13.2 to 19.7)
SecondaryOverall Survival (OS) Time (From Randomization to Cetuximab Maintenance Regimen Until Death)

The OS time is defined as the time from randomization in cetuximab maintenance regimen to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier.

Time frame:
Time from randomization in cetuximab maintenance regimen to death or last day known to be alive, reported between day of first participant randomized, that is, May 2009 until cut-off date (17 Dec 2011)
Reported as:
Median · months
Overall Survival (OS) Time (From Randomization to Cetuximab Maintenance Regimen Until Death)
monthsCetuximab 500 mg/m^2 Every 2 WeeksCetuximab 250 mg/m^2 Weekly
Overall Survival (OS) Time (From Randomization to Cetuximab Maintenance Regimen Until Death)12.6 (10.1 to 14.8)12.6 (9.3 to 16.0)
Statistical analysis
  • Cetuximab 500 mg/m^2 Every 2 Weeks vs Cetuximab 250 mg/m^2 Weekly · Log Rank · p = 0.1265 · Hazard ratio, log: 0.959 · 95% CI 0.736 to 1.250
SecondaryTime to Treatment Failure

Time to treatment failure is defined as the time from trial inclusion to date of either first occurrence of progression, discontinuation of treatment due to progression or adverse event, withdrawal of consent or lost to follow up, start of further anticancer therapy, or death, whichever is earlier. Participants without events are censored either at the time of their last drug intake, or on the day of inclusion (Day 1) if they received no study drug.

Time frame:
Time from trial inclusion to treatment failure or last drug intake, reported between day of first participant included, that is, Jan 2009 until cut-off date (17 Dec 2011)
Reported as:
Median · months
Time to Treatment Failure
monthsCetuximab 500 mg/m^2 Every 2 WeeksCetuximab 250 mg/m^2 Weekly
Time to Treatment Failure5.8 (5.6 to 6.6)6.6 (6.1 to 6.9)
SecondaryTime to Treatment Failure (From Randomization to Cetuximab Maintenance Regimen Until Death)

Time from randomization in cetuximab maintenance regimen to date of either first occurrence of progression, discontinuation of treatment due to progression or adverse event, withdrawal of consent or lost to follow up, start of further anticancer therapy, or death, whichever is earlier. Participants without events are censored either at the time of their last drug intake, or on the day of randomization (Day 1 of maintenance therapy) if they received no study drug.

Time frame:
Time from randomization in cetuximab maintenance regimen to treatment failure or last drug intake, reported between day of first participant randomized, that is, May 2009 until cut-off date (17 Dec 2011)
Reported as:
Median · months
Time to Treatment Failure (From Randomization to Cetuximab Maintenance Regimen Until Death)
monthsCetuximab 500 mg/m^2 Every 2 WeeksCetuximab 250 mg/m^2 Weekly
Time to Treatment Failure (From Randomization to Cetuximab Maintenance Regimen Until Death)2.6 (2.1 to 2.8)2.8 (2.6 to 4.0)
Statistical analysis
  • Cetuximab 500 mg/m^2 Every 2 Weeks vs Cetuximab 250 mg/m^2 Weekly · Log Rank · p = 0.0622 · Hazard ratio (hr): 0.774 · 95% CI 0.613 to 0.976
SecondaryPercentage of Participants With Best Unconfirmed Tumor Response in the Combination Therapy Phase

The response rate is defined as the percentage of participants having achieved complete response (CR) or partial response (PR) as the unconfirmed best overall response (BOR) according to centrally reviewed investigator assessments based on an independent review charter (IRC). As per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: CR = Disappearance of all target lesions; PR = at least 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Time frame:
Evaluations were performed every 2 cycles during combination therapy period until progression and at the end of combination therapy period, reported between day of first participant included, that is, Jan 2009, until cut-off date, (17 Dec 2011)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Unconfirmed Tumor Response in the Combination Therapy Phase
percentage of participantsCetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy
Percentage of Participants With Best Unconfirmed Tumor Response in the Combination Therapy Phase36.2 (32.3 to 40.2)
SecondaryPercentage of Participant With Best Unconfirmed Tumor Response for the Whole Study Period

The response rate is defined as the percentage of participants having achieved CR and PR as the BOR according to IRC assessment in combination therapy phase and radiological assessments (based on response evaluation criteria in solid tumors \[RECIST\] Version 1.0) in the maintenance therapy phase. As per RECIST v1.0 for target lesions and assessed by MRI: CR = Disappearance of all target lesions; PR = at least 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Time frame:
Evaluations were performed every 2 cycles during combination therapy and 6-weekly during maintenance therapy period until progression and at end of both periods, reported between day of first participant included, Jan 2009 until cut-off date (17 Dec 2011)
Reported as:
Number · percentage of participants
Percentage of Participant With Best Unconfirmed Tumor Response for the Whole Study Period
percentage of participantsCetuximab 500 mg/m^2 Every 2 WeeksCetuximab 250 mg/m^2 Weekly
Percentage of Participant With Best Unconfirmed Tumor Response for the Whole Study Period54.8 (46.6 to 62.7)57.8 (49.6 to 65.7)
SecondaryPercentage of Participants With Disease Control in the Combination Therapy Phase

The disease control rate is defined as the percentage of participants having achieved complete response or partial response or stable disease as the unconfirmed BOR according to IRC assessment.

Time frame:
Evaluations were performed every 2 cycles during combination therapy period until progression and at the end of combination therapy period, reported between day of first participant included, that is, Jan 2009, until cut-off date, (17 Dec 2011)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control in the Combination Therapy Phase
percentage of participantsCetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy
Percentage of Participants With Disease Control in the Combination Therapy Phase65.7 (61.7 to 69.5)
SecondaryPercentage of Participants With Disease Control for the Whole Study Period

The disease control rate is defined as the percentage of participants having achieved complete response or partial response or stable disease as the unconfirmed best overall response according to IRC assessment in combination therapy phase and radiological assessments (based on RECIST Version 1.0 criteria) in the maintenance therapy phase.

Time frame:
Evaluations were performed every 2 cycles during combination therapy and 6-weekly during maintenance therapy period until progression and at end of both periods, reported between day of first participant included, Jan 2009 until cut-off date (17 Dec 2011)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control for the Whole Study Period
percentage of participantsCetuximab 500 mg/m^2 Every 2 WeeksCetuximab 250 mg/m^2 Weekly
Percentage of Participants With Disease Control for the Whole Study Period98.7 (95.5 to 99.8)99.4 (96.4 to 100)
PrimaryPercentage of Participants With 1-year Overall Survival

The OS time is defined as the time from trial inclusion to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier. Percentage of participants who were still alive until one year after the last participant was included (March 2010).

Time frame:
Time from trial inclusion to death or last day known to be alive, reported between day of first participant included, that is, Jan 2009 until one year after the last participant was included (March 2010)
Reported as:
Number · percentage of participants
Percentage of Participants With 1-year Overall Survival
percentage of participantsCetuximab 500 mg/m^2 Every 2 WeeksCetuximab 250 mg/m^2 Weekly
Percentage of Participants With 1-year Overall Survival62.8 (54.7 to 70.0)64.4 (56.2 to 71.4)

Adverse events

Collected over Time from Baseline up to 30 days after the last dose of study treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy—243/583 (41.7%)564/583 (96.7%)
Cetuximab 500 mg/m^2 Every 2 Weeks—30/156 (19.2%)121/156 (77.6%)
Cetuximab 250 mg/m^2 Weekly—33/155 (21.3%)136/155 (87.7%)
Most frequent serious events
Showing 10 of 171
Most frequent serious events
EventCetuximab 250 mg/m^2 q1w + Platinum-based Doublet ChemotherapyCetuximab 500 mg/m^2 Every 2 WeeksCetuximab 250 mg/m^2 Weekly
NeutropeniaBlood and lymphatic system disorders32/5831/1560/155
Febrile NeutropeniaBlood and lymphatic system disorders20/5830/1560/155
PneumoniaInfections and infestations17/5834/1564/155
ThrombocytopeniaBlood and lymphatic system disorders13/5830/1560/155
Pulmonary embolismRespiratory, thoracic and mediastinal disorders12/5830/1561/155
VomitingGastrointestinal disorders11/5830/1561/155
DyspnoeaRespiratory, thoracic and mediastinal disorders10/5832/1562/155
DiarrhoeaGastrointestinal disorders9/5830/1560/155
PyrexiaGeneral disorders9/5830/1561/155
LeukopeniaBlood and lymphatic system disorders8/5830/1560/155
Most frequent other events
Showing 10 of 64
Most frequent other events
EventCetuximab 250 mg/m^2 q1w + Platinum-based Doublet ChemotherapyCetuximab 500 mg/m^2 Every 2 WeeksCetuximab 250 mg/m^2 Weekly
RashSkin and subcutaneous tissue disorders306/58340/15640/155
NauseaGastrointestinal disorders212/5833/1569/155
NeutropeniaBlood and lymphatic system disorders208/5830/1560/155
AnaemiaBlood and lymphatic system disorders134/5839/15615/155
AstheniaGeneral disorders124/5836/15616/155
VomitingGastrointestinal disorders122/5832/1568/155
DiarrhoeaGastrointestinal disorders120/5836/15615/155
FatigueGeneral disorders114/5837/15613/155
ThrombocytopeniaBlood and lymphatic system disorders112/5830/1560/155
Decreased appetiteMetabolism and nutrition disorders112/5838/15613/155

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy
Mean60.4 ± 9.28
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy
Female147
Male436
08

Study locations

1 site
  • Central Contact
    Darmstadt, Germany
09

References and documents

Publications

  • Heigener DF, Pereira JR, Felip E, Mazal J, Manzyuk L, Tan EH, Merimsky O, Sarholz B, Esser R, Gatzemeier U. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial. Target Oncol. 2015 Jun;10(2):255-65. doi: 10.1007/s11523-014-0336-7. Epub 2014 Sep 9. PubMed 25195590 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Dec 2011 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2009
First posted
Jan 12, 2009
Start
Jan 2009
Primary completionActual
Dec 2011
CompletionActual
Jun 2013
Results first posted
May 5, 2014
Last update
May 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00820755
Responsible party
Sponsor
First posted
Jan 12, 2009
Start date
Jan 2009
Primary completion
Dec 2011
Completion
Jun 2013
Results posted
May 5, 2014
Last update
May 5, 2014

Study contacts

Steffen Heeger, MD MSc
study director · Merck KGaA, Darmstadt, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion